[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,625,248
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,629 M
  • EBITDA $ 4,173 M
  • 60-Month Beta 0.24
  • Price/Sales 5.44
  • Price/Cash Flow 17.59
  • Price/Book 2.46

Options Overview Details

View History
  • Implied Volatility 31.97% (+1.41%)
  • Historical Volatility 31.93%
  • IV Percentile 20%
  • IV Rank 25.24%
  • IV High 49.01% on 10/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 4) 21.29 (2.80%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 2,194
  • Volume Avg (30-Day) 1,690
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 39,427
  • Open Int (30-Day) 38,785
  • Expected Range 737.95 to 780.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $10.46
  • Number of Estimates 7
  • High Estimate $12.48
  • Low Estimate $7.24
  • Prior Year $9.63
  • Growth Rate Est. (year over year) +8.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
637.72 +19.06%
on 07/06/26
772.75 -1.75%
on 08/03/26
+104.97 (+16.04%)
since 07/02/26
3-Month
591.52 +28.35%
on 06/02/26
772.75 -1.75%
on 08/03/26
+57.82 (+8.24%)
since 05/01/26
52-Week
541.00 +40.34%
on 10/13/25
821.11 -7.53%
on 01/09/26
+200.37 (+35.85%)
since 08/01/25

Most Recent Stories

More News
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Aug. 3, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals,...

REGN : 759.24 (-0.44%)
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN

LOS ANGELES , Aug. 3, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ: REGN...

REGN : 759.24 (-0.44%)
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSS

SAN FRANCISCO , July 31, 2026 /PRNewswire/ -- Regeneron Pharmaceuticals (NASDAQ: REGN)  faces a securities class action lawsuit after its surprising revelations concerning a Phase 3 clinical...

REGN : 759.24 (-0.44%)
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Early-career scientists from New York University, Stanford University and Rensselaer Polytechnic Institute were recognized for their ambitious "dream project" proposals TARRYTOWN, N.Y., July 31,...

REGN : 759.24 (-0.44%)
REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

REGN Q2 Deep Dive: Pipeline Progress and Product Momentum Drive Outperformance

REGN : 759.24 (-0.44%)
REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026

Important Notice Regarding Alleged Phase III Fianlimab-Libtayo Clinical Trial Risk Misrepresentations. The lawsuit alleges Regeneron investors overpaid while the Company characterized slowing...

REGN : 759.24 (-0.44%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN

NEW YORK , July 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such...

REGN : 759.24 (-0.44%)
Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

Regeneron’s (NASDAQ:REGN) Q2 CY2026: Strong Sales

REGN : 759.24 (-0.44%)
Regeneron: Q2 Earnings Snapshot

Regeneron: Q2 Earnings Snapshot

REGN : 759.24 (-0.44%)
Regeneron Reports Second Quarter 2026 Financial and Operating Results

Second quarter 2026 revenues increased 17% to $4.3 billion versus second quarter 2025 Dupixent ® global net sales (recorded by Sanofi) increased 38% to a new all-time high of $6.0 billion...

REGN : 759.24 (-0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 785.49
2nd Resistance Point 779.12
1st Resistance Point 769.18
Last Price 759.24
1st Support Level 752.87
2nd Support Level 746.50
3rd Support Level 736.56

See More

52-Week High 821.11
Last Price 759.24
Fibonacci 61.8% 714.11
Fibonacci 50% 681.05
Fibonacci 38.2% 648.00
52-Week Low 541.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.